Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 19/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 17/20 | 0.64 |
| ▸ | NPY5R | Q15761 | 11/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034967 | 1.00 | MCHR1 (0.64) | MCHR1ADRA2ANPY5RMAPT | |
| SCHEMBL4034024 | 0.91 | MCHR1 (0.74) | MCHR1ADRA2ANPY5R | |
| SCHEMBL5526620 | 0.91 | MCHR1 (0.74) | MCHR1ADRA2ANPY5R | |
| SCHEMBL5524275 | 0.89 | MCHR1 (0.62) | MCHR1ADRA2ANPY5R | |
| SCHEMBL5524271 | 0.89 | MCHR1 (0.62) | MCHR1ADRA2ANPY5R | |
| SCHEMBL4037620 | 0.89 | MCHR1 (0.52) | MCHR1ADRA2ANPY5RMAPT | |
| SCHEMBL4037618 | 0.89 | MCHR1 (0.52) | MCHR1ADRA2ANPY5RMAPT | |
| Trifluoroacetic Acid SCHEMBL4354265 | 0.88 | MCHR1 (0.66) | MCHR1ADRA2ANPY5R | |
| SCHEMBL5522577 | 0.84 | MCHR1 (0.58) | MCHR1ADRA2ANPY5R | |
| SCHEMBL5522584 | 0.84 | MCHR1 (0.58) | MCHR1ADRA2ANPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611109-A4 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO LTD (JP) | 2009-06-24 | — | — | EP | disclosed |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
| EP-1611109-A1 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004087680-A1 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | MCHR1 1/4885ADRA2A 103/4885NPY5R 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.